| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| INR-H52Ha | Human | Human Insulin R / CD220 (28-944) Protein, His Tag (SPR verified) |  |
|
|
Human Insulin R (28-944), His Tag (Cat. No. INR-H52Ha) captured on CM5 chip via anti-His antibody, can bind Human Insulin with an affinity constant of 249 nM as determined in a SPR assay (Biacore T200) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Rinsulin NPH (Geropharm) | Approved | GEROPHARM | Diabetes | Details | ||||||
| Insulin degludec | NN-1250; Insulin-454,NN1250 | Approved | Novo Nordisk | Insulin degludec | 日本 | Diabetes | 诺和诺德 | 2012-09-28 00:00:00.0 | Diabetes, Type 1 diabetes, Type 2 diabetes | Details |
| Human insulin biosimilar (Square Pharmaceuticals) | Approved | Square Pharmaceuticals | Diabetes | Details | ||||||
| Oral insulin (Generex Biotechnology) | Approved | Generex Biotechnology Corporation, SciVac Ltd, PharmaBrand, DongSung Pharm | Type 1 diabetes, Type 2 diabetes | Details | ||||||
| Recombinant human insulin (Shenzhen Kexing Biotech) | Approved | Shenzhen kexing, Shenzhen kexing | Diabetes | Details | ||||||
| Insulin glargine biosimilar (Lilly/Boehringer Ingelheim) | LY-2963016; LY2963016-U-100; LY2963016-U-200,LY2963016 | Approved | Lilly, Boehringer Ingelheim | insulin glargine | ema | Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
Eli Lilly Nederland B.V. | 2014-09-09 | Type 1 diabetes, Type 2 diabetes | Details |
| Recombinant human insulin (SciGen) | Approved | Generex Biotechnology Corporation, SciVac Ltd | Diabetes | Details | ||||||
| Human insulin biosimilar (MJ Biopharm) | Approved | MJ Biopharm Pvt | Diabetes | Details | ||||||
| Recombinant Human Insulin (Wanbang Pharma) | Approved | Wanbang Biopharmaceuticals | Recombinant Human Insulin Injection | cfda | Diabetes | 2015-08-25 | Diabetes | Details | ||
| Insulin biosimilar (Julphar) | Approved | Julphar Gulf Pharmaceutical Industries | Diabetes | Details | ||||||
| Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX,LDK378,LDK 378 | Approved | Novartis | ZYKADIA | fda | Non small cell lung cancer (NSCLC) | NOVARTIS | 2014-04-29 | Non small cell lung cancer (NSCLC) | Details |
| Insulin human (rDNA origin, Novo Nordisk) | NN-729,NN729 | Approved | Novo Nordisk | Mixtard 50/50 | hma | Diabetes | Novo Nordisk A/S Novo Alle DK-2880 Bagsv?rd |
1996-07-29 | Diabetes | Details |
| Isophane Protamine Recombinant Human Insulin Injection (Shenzhen Kexing Biotech) | Approved | Shenzhen kexing | Isophane Protamine Recombinant Human Insulin Injection | cfda | Diabetes | 2015-04-30 | Diabetes | Details | ||
| Rosinsulin | Approved | Medsintez | Diabetes | Details | ||||||
| Insulin glargine biosimilar (Incepta Pharmaceuticals) | Approved | Incepta Pharmaceuticals | Type 1 diabetes, Type 2 diabetes | Details | ||||||
| Insulin biosimilar (Harvest Moon Pharmaceuticals) | Approved | Harvest Moon | Diabetes | Details | ||||||
| Insulin aspart | NN-1218; INA-X14; Insulin X14 | Approved | Novo Nordisk | insulin aspart | ema | NovoRapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. |
Novo Nordisk A/S | 1999-09-07 | Diabetes | Details |
| Insulin N biosimilar (Popular Pharmaceuticals) | Approved | Popular Pharmaceuticals | Diabetes | Details | ||||||
| Insulin glargine biosimilar (LG Life Sciences) | Approved | LG Life Sciences, Lupin | Type 1 diabetes, Type 2 diabetes | Details | ||||||
| Recombinant lispro insulin biosimilar (Gan & Lee) | Approved | Gan & Lee Biotech | Recombinant Lispro Insulin Injection | cfda | Diabetes | 2015-11-30 | Diabetes | Details | ||
| Insulin biosimilar (Popular Pharmaceuticals) | Approved | Popular Pharmaceuticals | Diabetes | Details | ||||||
| Isophane Insulin | Approved | Wanbang Biopharmaceuticals | Isophane Insulin Injection | cfda | Diabetes | 2015-08-25 | Diabetes | Details | ||
| Recombinant human insulin (Incepta) | Approved | Incepta Pharmaceuticals | Diabetes | Details | ||||||
| Insulin aspart biosimilar (Sanofi) | SAR 341402; SAR-Asp | Approved | Sanofi | insulin aspart | ema | Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. |
sanofi-aventis groupe | 2020-06-25 | Type 1 diabetes, Type 2 diabetes | Details |
| Insulin lispro | LY-275585; Lys-B28; Pro-B29; LYSPRO; LY-900027 | Approved | Lilly | insulin lispro | ema | Eli Lilly Nederland B.V. | 1996-04-30 | Diabetes | Details | |
| Recombinant human insulin (Biocon) | Approved | Biocon | Diabetes | Details | ||||||
| Insulin human | HR-1799 | Approved | Sanofi Deutschland | insulin human | ema | Sanofi-aventis Deutschland GmbH | 2007-01-17 | Diabetes, Cerebral edema diabetic ketoacidosis | Details | |
| Insulin biosimilar (Sedico) | Approved | Sedico | Diabetes | Details | ||||||
| Insulin degludec/Insulin aspart | NN-5401; NN-1045; NN-1250/Insulin aspart | Approved | Novo Nordisk A/S | Insulin degludec/Insulin aspart | 日本 | Diabetes | 诺和诺德 | 2012-12-25 00:00:00.0 | Diabetes, Type 1 diabetes, Type 2 diabetes | Details |
| Insulin detemir | NN-304 | Approved | Novo Nordisk | Insulin detemir | ema | Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. |
Novo Nordisk A/S | 2004-06-01 | Type 1 diabetes, Diabetes | Details |
| Recombinant insulin (Horizon Pharma/Ibatech) | Approved | Savient Pharmaceuticals, Horizon, Ibatech Sp. zo.o | Type 1 diabetes | Details | ||||||
| Insulin degludec/Liraglutide | NN-9068,NN9068 | Approved | Novo Nordisk | insulin degludec;liraglutide | ema | Novo Nordisk A/S | 2014-09-18 | Type 2 diabetes | Details | |
| Insulin glargine biosimilar (Wockhardt) | Approved | Wockhardt | Diabetes, Type 1 diabetes, Type 2 diabetes | Details | ||||||
| Recombinant insulin glargine (Gan & Lee) | Approved | Gan & Lee Biotech | Recombinant Insulin Glargine Injection | cfda | Diabetes | 2015-02-03 | Diabetes | Details | ||
| Insulin glargine biosimilar (Getz Pharma) | Approved | Getz Pharma | Type 1 diabetes, Type 2 diabetes | Details | ||||||
| Insulin lispro biosimilar (Sanofi) | SAR-342434 | Approved | Sanofi | insulin lispro | ema | sanofi-aventis groupe | 2017-07-18 | Diabetes | Details | |
| Insulin glulisine | HMR-1964,HMR1964 | Approved | Sanofi | APIDRA | fda | Type 1 diabetes, Diabetes | SANOFI AVENTIS US | 2004-04-16 | Type 1 diabetes, Diabetes | Details |
| Insul 30/70 biosimilar (Popular Pharmaceuticals) | Approved | Popular Pharmaceuticals | Type 1 diabetes, Gestational diabetes mellitus, Type 2 diabetes | Details | ||||||
| Bacitracin | Approved | Pfizer | Bacterial infection | Details | ||||||
| Insulin glargine biosimilar (Biocon) | MYL-1501D | Approved | Biocon BioPharmaceuticals, FUJIFILM Corporation, Mylan | 日本 | Diabetes | FUJIFILM Corporation | 2016-03-28 00:00:00.0 | Diabetes | Details | |
| Insulin glargine biosimilar (Merck Sharp & Dohme) | MK-1293; SB-9 | Approved | Samsung Bioepis, Merck Sharp & Dohme | insulin glargine | ema | Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. |
Merck Sharp & Dohme B.V. | 2017-01-03 | Type 1 diabetes, Type 2 diabetes | Details |
| Recombinant human insulin (Tonghua Dongbao Pharmaceutical) | Approved | Tonghua Dongbao Pharmaceutical | Isophane Protamine Recombinant Human Insulin Injection | cfda | Diabetes | 2015-08-18 | Diabetes | Details | ||
| Insulin human (inhalation powder) | SAR-439065,SAR439065 | Approved | MannKind Corporation, Sanofi | AFREZZA | fda | Diabetes | MANNKIND | 2014-06-27 | Diabetes | Details |
| Insulin human (rDNA origin, Lilly) | S-3300; LY-041001; U-500R | Approved | Lilly | HUMULIN R | fda | Diabetes | LILLY | 1982-10-28 | Diabetes | Details |
| Recombinant human insulin (United Laboratories International Holdings) | Approved | United Laboratories Zhongshan Branch | Isophane Protamine Recombinant Human Insulin Injection | cfda | Diabetes | 2014-11-24 | Diabetes | Details | ||
| Insulin glargine | Gla-100; Gla-300; HOE901-U300; Hoe-71GT; Hoe-901; U-300 | Approved | Sanofi | LANTUS SOLOSTAR | fda | Type 2 diabetes, Type 1 diabetes | SANOFI AVENTIS US | 2000-04-20 | Diabetes, Type 1 diabetes, Type 2 diabetes | Details |
| Insulin biosimilar (Wockhardt) | Approved | Wockhardt | Type 1 diabetes | Details | ||||||
| Insulin glargine/Lixisenatide | HOE-901/AVE-0010 | Approved | Sanofi | SOLIQUA 100/33 | fda | Type 2 diabetes | SANOFI-AVENTIS US | 2016-11-21 | Type 2 diabetes | Details |
| Insulin lispro protamine biosimilar (Gan & Lee Pharmaceuticals) | Approved | Gan & Lee Biotech | Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection(25R) | cfda | Diabetes | 2014-05-09 | Diabetes | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant human insulin (HEC Pharm) | BLA Filing | HEC Pharm, Yichang HEC Changjiang Pharmaceutical | Diabetes | Details | |
| INS-061 | INS-061; HS-061 | IND Filing | Shanghai Hengrui | Diabetes | Details |
| Insulin icodec | 148-0287-A; Insulin-287; LAI-287; Long-acting basal insulin analogue; Long-acting-insulin-287; NN-1436; NN-1956; NNC-0148-0000-0287; NNC0148-0287 C; OI-287GT | Phase Ⅲ | Novo Nordisk | Type 2 diabetes | Details |
| Insulin glargine biosimilar (YiChang HEC ChangJiang Pharmaceutical) | Phase Ⅲ | HEC Pharm, Lannett | Diabetes | Details | |
| Stem cell therapy (RejuvaCell) | Phase Not Specified | RejuvaCell | Type 2 diabetes | Details | |
| Insulin lispro/Insulin glargine | Phase Ⅱ | Adocia | Type 1 diabetes, Type 2 diabetes | Details | |
| Insulin detemir biosimilar (Tonghua Dongbao Pharmaceutical) | Phase Ⅰ | Tonghua Dongbao Pharmaceutical | Diabetes | Details | |
| Insulin prandial injectable (Albireo Pharma) | VIAject-25; VIAject-7 | BLA Filing | Albireo | Type 1 diabetes, Diabetes, Type 2 diabetes | Details |
| Insulin oral (Emisphere Technologies) | Phase Ⅱ | Emisphere Technologies | Type 2 diabetes | Details | |
| Insulin aspart biosimilar (Gan & Lee) | BLA Filing | Gan & Lee Biotech | Type 1 diabetes, Type 2 diabetes | Details | |
| NN-1406 | NN-1406; NNC0143-0406; NNC0143-0406 A; PI-406 | Phase Ⅰ | Novo Nordisk | Type 1 diabetes, Type 2 diabetes | Details |
| Insulin glargine biosimilar(Shandong New Time Pharmaceutical) | BLA Filing | Lunan Pharmaceutical Group Corporatio | Diabetes | Details | |
| Insulin (Oramed Pharmaceuticals) | ORMD-0801 | Phase Ⅱ | Oramed Pharmaceuticals, Hefei Tianhui Incubator of Technologies | Type 1 diabetes, Type 2 diabetes | Details |
| Bacitracin/Tranexamic acid | IPI-120 | Preclinical | Imprimis Pharmaceuticals | wound, Wound infections | Details |
| Recobinant human proinsulin C peptide (Shanghai Newsummit/Shanghai Yizhong) | Phase Ⅰ | Shanghai Newsummit Biopharma | Diabetic nephropathy | Details | |
| Insulin lispro (Diasome Pharmaceuticals) | Phase Ⅱ | Diasome Pharmaceuticals | Type 1 diabetes | Details | |
| Transdermal insulin patch (Dermisonics) | Phase Ⅰ | Dermisonics, Encapsulation Systems, Transdermal Global | Diabetes | Details | |
| Insulin biosimilar (Hefei Tianmai Biotechnology) | Phase Ⅲ | Hefei Tianmai Biotechnology | Diabetes | Details | |
| Insulin adjustable basal (Biodel) | BIOD-809 | Phase Ⅰ | Albireo | Diabetes | Details |
| Transdermal insulin patches (SK Chemicals) | Phase Ⅲ | SK Chemicals | Type 1 diabetes | Details | |
| Insulin glargine biosimilar (Wanbang Biochemical) | Phase Ⅲ | Wanbang Biopharmaceuticals | Type 2 diabetes | Details | |
| DM199 | DM-199; DM-99 | Phase Ⅱ | DiaMedica | Stroke, Type 2 diabetes, Chronic kidney disease | Details |
| PE-0139 | PE-0139 | Phase Ⅱ | PhaseBio | Type 2 diabetes | Details |
| Ultra-rapid-acting insulin analogue (Albireo Pharma) | BIOD-238 | Phase Ⅰ | Albireo | Type 1 diabetes | Details |
| Insulin transdermal (TransPharma Medical) | Phase Not Specified | TransPharma Medical | Type 1 diabetes, Type 2 diabetes | Details | |
| Transbuccal insulin (MidaSol) | MSRX-301; MSL-001; MTD-101 | Phase Ⅱ | Midatech, Aquestive Therapeutics | Type 1 diabetes | Details |
| Basal insulin peglispro | LY-2605541,LY2605541 | Phase Ⅲ | Lilly, Boehringer Ingelheim | Type 1 diabetes, Type 2 diabetes | Details |
| Insulin mouth rinse (EastGate Biotech) | Phase Ⅲ | Eastgate Biotech, Genome Pharmaceuticals | Type 1 diabetes, Type 2 diabetes, Alzheimer's disease (AD) | Details | |
| Recombinant human insulin biosimilar (Rechon Life Sciences) | Phase Ⅲ | Rechon Life Science | Type 1 diabetes | Details | |
| KW-2450 | KW-2450 | Phase Ⅱ | Kyowa Hakko Kirin | Breast cancer | Details |
| Recombinant insulin aspart biosimilar (Biogenomics) | Phase Ⅲ | Biogenomics | Type 2 diabetes | Details | |
| Ultra fast-acting insulin analogue | BC-106-Insulin-Lispro; BC-222-Insulin-Lispro | Phase Ⅲ | Adocia, Lilly, Tonghua Dongbao Pharmaceutical | Type 1 diabetes, Type 2 diabetes | Details |
| Insulin receptor-regulating antibodies (XOMA) | X-129; XMet program; XMetA; XMetD;XMetS; XOMA-129 | Preclinical | Xoma | Diabetes, Hypoglycemia | Details |
| SAR-161271 | SAR 161271,SAR-161271,SAR161271 | Phase Ⅱ | Sanofi | Type 1 diabetes | Details |
| NN-344 | NN-344 | Phase Ⅰ | Novo Nordisk A/S | Type 1 diabetes, Type 2 diabetes | Details |
| Insulin inhalation (Aerogen) | Phase Ⅱ | Nektar | Diabetes | Details | |
| Insulin rectal (Oramed Pharmaceuticals) | ORMD-0802 | Phase Ⅰ | Oramed Pharmaceuticals | Type 1 diabetes | Details |
| Oral insulin (Purede) | Phase Not Specified | Puredel | Diabetes | Details | |
| Insulin glargine biosimilar (Tonghua Dongbao Pharmaceutical) | BLA Filing | Tonghua Dongbao Pharmaceutical | Diabetes | Details | |
| Human insulin biosimilar (Marvel Lifesciences) | BLA Filing | Marvel LifeSciences Private | Diabetes | Details | |
| Fast-acting human insulin (Adocia) | BioChaperone-222; Hinsbet-U500 | Phase Ⅱ | Adocia | Type 1 diabetes | Details |
| Recombinant human insulin (Nutrinia) | NTRA-9620,NTRA 9620,NTRA9620 | Phase Ⅲ | Nutrinia | Short bowel syndrom | Details |
| Insulin lispro biosimilar (Valin Technologies) | Preclinical | Valin Technologies | Diabetes | Details | |
| Insulin polysialic (Xenetic Biosciences) | SYN-20090110-RU; SYN-20090510-RU | Phase Ⅰ | Lipoxen Technologies, SynBio, Xenetic Biosciences | Type 1 diabetes, Central nervous system disorders, Type 2 diabetes | Details |
| Insulin biosimilars (Bioton) | Phase Not Specified | Bioton | Diabetes | Details | |
| Insulin inhalation (Andaris) | Phase Ⅰ | Elan Corporation | Diabetes | Details | |
| Oral insulin-338-C10 | Insulin-338-GIPET-I; LAI-338; NN-1438; NN-1953; NNC0123-0338; OI-338GT; Oral insulin 338 C10 | Phase Ⅱ | Novo Nordisk, Merrion Pharmaceuticals | Type 1 diabetes, Type 2 diabetes | Details |
| Ultra-rapid-acting insulin analogues (Albiero Pharma) | BIOD-250 | Phase Ⅰ | Albireo | Type 1 diabetes | Details |
| Dulaglutide/Basal insulin Fc | Phase Ⅰ | Lilly | Diabetes | Details | |
| Linsitinib | ASP-7487; OSI-906; OSI-906AA,ASP7487,OSI906,OSI906AA | Phase Ⅲ | Astellas, National Cancer Institute | Adrenocortical carcinoma | Details |
| Insulin biosimilar (Valin Technologies) | Van-101,Van 101,Van101 | Phase Ⅲ | Valin Technologies | Diabetes | Details |
| EX-1000 | EX1000,EX 1000 | Phase Ⅱ | Novo Nordisk | Type 2 diabetes | Details |
| Insulin human (Pfizer) | HMR 4006 | Withdrawn | Pfizer, Nektar | Diabetes | Details |
| Insulin aspart biosimilar (Zhuhai United Laboratories) | BLA Filing | United Laboratories | Type 1 diabetes, Type 2 diabetes | Details | |
| INS-068 | INS-068,INS068; INS 068 | Phase Ⅰ | Jiangsu Hengrui Medicine, Chengdu Shengdi, Shanghai Hengrui | Type 1 diabetes, Type 2 diabetes | Details |
| Insulins (Halozyme) | Analog insulin-PH20; Aspart-PH20;Insulin-PH20; Lispro-PH20; rHuPH20/insulin | Phase Ⅱ | Halozyme Therapeutics | Type 1 diabetes, Type 2 diabetes | Details |
| Intranasal insulin (Johns Hopkins University) | Phase Ⅱ | Johns Hopkins University | HIV-associated neurocognitive disorder, Multiple sclerosis (MS) | Details | |
| Insulin (Altea Therapeutics) | AT-1391 | Phase Ⅱ | Nitto Denko | Type 1 diabetes, Type 2 diabetes | Details |
| Human insulin/EDTA/Citrate/Magnesium sulfate (Biodel) | BIOD-123 | Phase Ⅱ | Albireo | Type 1 diabetes | Details |
| MK-2640 | MK-2640,MK2640,MK 2640 | Phase Ⅰ | Merck Sharp & Dohme | Type 1 diabetes | Details |
| recombinant human insulin | CKD-401,CKD 401,CKD401 | Phase Ⅲ | Chong Kun Dang | Diabetes | Details |
| Insulin glargine biosimilar (Valin Technologies) | Phase Ⅰ | Valin Technologies | Diabetes | Details | |
| AB-101 (Rezolute) | AB-101 | Phase Ⅰ | IPR Pharmaceuticals, Rezolute, Xoma | Type 1 diabetes | Details |
| 重组赖精胰岛素（合肥天麦） | Phase Ⅲ | Hefei Tianmai Biotechnology | Diabetes | Details | |
| Insulin inhalation (MAP Pharmaceuticals) | MAP-0001 | Phase Ⅰ | Allergan | Type 1 diabetes, Type 2 diabetes | Details |
| Insulin biosimilar (University of Montreal Health Centre) | Phase Ⅰ | University of Montreal Health Centre | Glaucoma | Details | |
| Insulin oral (Diabetology) | DTY-001 | Phase Ⅱ | Diabetology Ltd, USV | Type 1 diabetes, Type 2 diabetes | Details |
| NN-1954 (Novo Nordisk) | NN-1954 | Phase Ⅰ | Novo Nordisk | Type 1 diabetes, Type 2 diabetes | Details |
| Concentrated ultra-rapid-acting insulin (Albireo Pharma) | BIOD-531 | Phase Ⅱ | Albireo | Type 2 diabetes | Details |
| Insulin glargine biosimilar (Geropharm) | Phase Ⅲ | GEROPHARM | Type 1 diabetes, Type 2 diabetes | Details | |
| NKTR-034 | NKTR-034 | Phase Ⅰ | Nektar | Diabetes | Details |
| BetaRx | Phase Ⅱ | Vivorx Pharmaceuticals | Diabetes | Details | |
| HM-12460A | HM-12470; HM-12470A; SAR-440067 | Phase Ⅰ | Hanmi | Type 1 diabetes, Type 2 diabetes | Details |
| Insulin inhaled (Translational Research) | Phase Ⅰ | Translational Research Ltd | Type 1 diabetes | Details | |
| Insulin inhalation (Abbott Laboratories) | KI-02212; KI-02-212 | Phase Ⅱ | Abbott | Diabetes | Details |
| Ultra fast-acting insulin lispro biosimilar (Perosphere) | URAL | Phase Ⅰ | Perosphere | Type 1 diabetes | Details |
| AI-401 | AI-401 | Phase Ⅲ | The National Institute of Diabetes and Digestive and Kidney Diseases | Type 1 diabetes | Details |
| Pegylated recombinant human insulin (Chongqing Fujin Biomedical) | Phase Ⅰ | Chongqing Fujin Biomedical | Diabetes | Details | |
| Insulin lispro biosimilar (Wanbang Biopharma) | Phase Ⅲ | Wanbang Biopharmaceuticals | Diabetes | Details | |
| CLX-0901 | CLX 0901 | Phase Ⅱ | Theracos | Type 2 diabetes | Details |
| Insulin aspart biosimilar (Geropharm) | GP-40071; GP-40081 | Phase Ⅲ | GEROPHARM | Diabetes | Details |
| Alirinetide | GM-6; GM-600; GM-602; GM-603; GM-604; GM-605; GM-606; GM-607; GM-608; GM-609 | Phase Ⅱ | Genervon | Amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Ischemic stroke | Details |
| HM-12470 | HM-12470A; SAR-440067; LAPS Insulin 115 | Phase Ⅰ | Hanmi, Sanofi | Type 1 diabetes, Type 2 diabetes | Details |
| Insulin inhalation (Lilly/Dura Pharmaceuticals) | Phase Ⅱ | Dura Pharmaceuticals, Lilly | Type 1 diabetes, Type 2 diabetes | Details | |
| Insulin 320 | OI320GT; NN-1957 | Phase Ⅰ | Novo Nordisk | Type 2 diabetes | Details |
| Insulin aspart biosimilar (Biocon/Mylan) | MYL-1601D | Phase Ⅲ | Biocon, Mylan | Type 1 diabetes | Details |
| Semaglutide/Insulin 287 | NNC0148-0287sema | Phase Ⅰ | Novo Nordisk | Type 2 diabetes | Details |
| Recombinant human insulin (Eastgate Biotech) | EGP-1214,EGP1214,EGP 1214 | Phase Not Specified | Eastgate Biotech | Type 2 diabetes, Prediabetes | Details |
| XOMA-358 | XOMA-358; XOMA-247; XPA.15.247 | Phase Ⅱ | Xoma | Hyperinsulinaemia, Hypoglycemia | Details |
| Insulin inhaled (Coremed) | Phase Ⅰ | CoreMed, Wanbang Biopharmaceuticals, Fosun Pharma | Diabetes | Details | |
| MBL protein (Bridge BioResearch) | Phase Ⅰ | Bridge BioResearch | Type 2 diabetes | Details | |
| Insulin (Coremed) | Phase Ⅰ | CoreMed | Diabetes | Details | |
| Insulin intranasal (Marina Biotech) | Phase Ⅱ | Marina Biotech, Autotelic | Type 2 diabetes | Details | |
| NN-1952 | NN-1952 | Phase Ⅰ | Novo Nordisk, Merrion Pharmaceuticals | Diabetes | Details |
| Basal insulin Fc (Eli Lilly) | Phase Ⅰ | Lilly | Diabetes | Details | |
| Insulin aspart biosimilar (Tonghua Dongbao Pharmaceutical) | Phase Ⅲ | Tonghua Dongbao Pharmaceutical | Diabetes | Details | |
| Insulin inhalation (Dong Sung/Biocon) | Phase Ⅱ | Biocon BioPharmaceuticals, DongSung Pharm | Type 1 diabetes | Details | |
| Insuman U-400 | BLA Filing | Sanofi | Type 1 diabetes | Details | |
| AKP-11 | AKP-11,AKP11 | Phase Ⅱ | Akaal Pharma | Plaque psoriasis | Details |
| Insulin oral (Provalis) | Phase Ⅱ | Provalis | Type 1 diabetes, Type 2 diabetes | Details | |
| Insulin (transoral) (Noven Pharmaceuticals) | Phase Ⅰ | Hisamitsu Pharmaceutical | Type 1 diabetes | Details | |
| NP-01 (Medesis Pharma SA) | NP01 | Phase Ⅰ | Medesis Pharma SA | Type 2 diabetes | Details |
| Oral insulin (Orin Pharmaceuticals) | Phase Ⅱ | Orin Pharmaceuticals | Type 2 diabetes | Details | |
| BIOD-125 (Biodel) | Phase Ⅰ | Albireo | Type 1 diabetes | Details | |
| Hepatoselective insulin (BTG/King's College London) | Phase Ⅰ | King's College London, BTG plc | Type 1 diabetes | Details |
This web search service is supported by Google Inc.
A-Z